Wednesday, July 12, 2017 2:42:19 PM
Recent OCUL News
- Ocular Therapeutix™ To Present at Two Ophthalmology Meetings, May 4-9, 2024 • GlobeNewswire Inc. • 05/03/2024 11:30:00 AM
- Ocular Therapeutix™ to Host Investor Day in New York City on Thursday, June 13, 2024 • GlobeNewswire Inc. • 05/01/2024 11:30:00 AM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 03/11/2024 08:23:22 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/11/2024 08:12:44 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/11/2024 08:10:50 PM
- U.S. Index Futures Dip Ahead of Inflation Data and Oracle’s Earnings; Oil Prices Edge Higher • IH Market News • 03/11/2024 10:39:47 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/27/2024 09:43:51 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/27/2024 01:07:55 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/27/2024 01:06:32 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 02/27/2024 01:04:11 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 02/27/2024 01:02:45 AM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 02/22/2024 01:00:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/22/2024 12:34:53 PM
- AffaMed Therapeutics Announces New Drug Application Acceptance by Singapore Health Sciences Authority (HSA) for DEXTENZA® for Treatment of Ocular Inflammation and Pain Following Ophthalmic Surgery, and Ocular Itching Associated with Allergic Conjunctiviti • PR Newswire (US) • 02/19/2024 02:00:00 PM
- Ocular Therapeutix™ Appoints Steve Meyers to Chief Commercial Officer • GlobeNewswire Inc. • 02/15/2024 01:00:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/15/2024 12:48:57 AM
- Ocular Therapeutix™ Announces First Subjects Screened in Phase 3 Pivotal Clinical Trial of AXPAXLI™ in Wet AMD • GlobeNewswire Inc. • 02/13/2024 12:37:51 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/06/2024 11:38:53 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/06/2024 11:35:58 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/06/2024 11:32:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/06/2024 11:29:51 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/06/2024 11:26:40 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/05/2024 09:41:52 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/05/2024 09:39:23 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/05/2024 09:36:38 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM